Journal: Pharmaceutics

Article Title: LPX-TI641, a Tim3/4 Agonist, Induces Long-Term Immune Tolerance in Multiple Sclerosis Models

doi: 10.3390/pharmaceutics17111402

Figure Lengend Snippet: LPX-TI641 Ameliorates Disease in the MOG 35–55 induced EAE mouse model. ( A ) Clinical scores of mice immunized with MOG 35–55 and treated at disease onset with varying doses of LPX-TI641 ( n = 10/group). ( B ) Comparison of clinical EAE scores in mice treated with GA (glatiramer acetate), natalizumab, or LPX-TI641 ( n = 10/group). ( C ) Clinical scores of EAE mice initially treated with natalizumab and subsequently switched to LPX-TI641 ( n = 10/group). ( D ) Microscopic imaging (10×) of Luxol Fast Blue staining of brain tissue from EAE mice treated with: ( i ) LPX-TI641 (Gr 6); ( ii ) a single dose of natalizumab (Gr 4); or ( iii ) two doses of natalizumab followed by LPX-TI641 (Gr 5). The LFB images are provided as qualitative illustrations of regions of demyelination and preserved myelin. Arrows highlight those regions for clarity.

Article Snippet: These mice either continued DMF (2 mg/mouse PO QD for 14 days), switched to natalizumab (100 μg/mouse IV every three days for three doses; MedChem Express, cat# HY-108831), or switched to LPX-TI641 (3 μg/mouse SC QD for 14 days) ( ).

Techniques: Comparison, Imaging, Staining

Journal: Pharmaceutics

Article Title: LPX-TI641, a Tim3/4 Agonist, Induces Long-Term Immune Tolerance in Multiple Sclerosis Models

doi: 10.3390/pharmaceutics17111402

Figure Lengend Snippet: LPX-TI641 Suppresses Relapse in the PLP-Induced EAE Mouse Model. ( A ) Clinical scores of mice immunized with PLP and treated on day 15 post-immunization with varying doses of LPX-TI641 ( n = 10/group). ( B ) Comparison of EAE clinical scores in mice treated with natalizumab or LPX-TI641 ( n = 10/group). ( C ) Clinical scores of EAE mice initially treated with natalizumab and subsequently switched to LPX-TI641 ( n = 10/group). ( D ) Flow cytometry plots showing CD4 + Foxp3 + T-reg expression in brain ( top ) and spleen ( bottom ) at day 21 post-immunization across different treatment groups.

Article Snippet: These mice either continued DMF (2 mg/mouse PO QD for 14 days), switched to natalizumab (100 μg/mouse IV every three days for three doses; MedChem Express, cat# HY-108831), or switched to LPX-TI641 (3 μg/mouse SC QD for 14 days) ( ).

Techniques: Comparison, Flow Cytometry, Expressing

Journal: Pharmaceutics

Article Title: LPX-TI641, a Tim3/4 Agonist, Induces Long-Term Immune Tolerance in Multiple Sclerosis Models

doi: 10.3390/pharmaceutics17111402

Figure Lengend Snippet: LPX-TI641 in an Escalation Treatment Paradigm in the MOG-Induced EAE Mouse Model. ( A ). Kaplan–Meier plot showing the efficacy of LPX-TI641 in delaying or preventing disease progression compared to dimethyl fumarate (DMF). ( B ) EAE clinical scores in mice treated with DMF vs. LPX-TI641 ( n = 10/group). ( C ) Clinical scores for mice treated with DMF followed by escalation to either LPX-TI641 or natalizumab ( n = 10/group). ( D ) Survival curves comparing treatment groups following therapeutic escalation paradigm.

Article Snippet: These mice either continued DMF (2 mg/mouse PO QD for 14 days), switched to natalizumab (100 μg/mouse IV every three days for three doses; MedChem Express, cat# HY-108831), or switched to LPX-TI641 (3 μg/mouse SC QD for 14 days) ( ).

Techniques: Biomarker Discovery

Journal: Pharmaceutics

Article Title: LPX-TI641, a Tim3/4 Agonist, Induces Long-Term Immune Tolerance in Multiple Sclerosis Models

doi: 10.3390/pharmaceutics17111402

Figure Lengend Snippet: LPX-TI641 in an Induction/Maintenance Paradigm in the MOG-Induced EAE Mouse Model. ( A ) Kaplan–Meier plot showing the efficacy of LPX-TI641 in controlling disease compared to natalizumab. ( B ) EAE clinical scores in mice treated with natalizumab or LPX-TI641 ( n = 10/group). ( C ) Survival curves for mice randomized to receive LPX-TI641 or natalizumab during disease progression. ( D ) Survival curves during maintenance therapy with LPX-TI641 or natalizumab. ( E ) Clinical scores of EAE in mice initially treated with natalizumab and then transitioned to maintenance therapy with either dimethyl fumarate (DMF) or LPX-TI641.

Article Snippet: These mice either continued DMF (2 mg/mouse PO QD for 14 days), switched to natalizumab (100 μg/mouse IV every three days for three doses; MedChem Express, cat# HY-108831), or switched to LPX-TI641 (3 μg/mouse SC QD for 14 days) ( ).

Techniques: Biomarker Discovery

Journal: Molecular Medicine

Article Title: Bleomycin induces senescence and repression of DNA repair via downregulation of Rad51

doi: 10.1186/s10020-024-00821-y

Figure Lengend Snippet: Increased senescence markers and reduced Rad51 Expression in vivo. A Schematic picture of the animal experiment. B Representative HE (Upper panel), Masson staining (Middle panel), and SA-β-Gal staining (Lower panel) of harvested mouse lung tissues. C Representative immunohistochemical analysis of Rad51 (brown) in lung sections. The control group showed strong positive staining for Rad51 compared to the BLM and BLM + NTZ + Anti-Ly6G group (Arrows). D Quantitative analysis of fibrosis was performed using the Ashcroft score. E The semi-quantitative assessment of immunohistochemistry was determined by ImageJ software. F The intensity of Rad51 immunofluorescence was quantified by ImageJ software. G Representative images of Rad51 expression in AECs by co-immunofluorescence staining with both Rad51 (green) and PDPN (red). Significance markers: *p < 0.05; ***p < 0.001 compared to control; n = 6

Article Snippet: Natalizumab (NTZ) and Anti-Mouse Ly-6G/Ly-6C Antibody (Anti-Ly6G) were procured from MedChemExpress (MCE, Shanghai, China).

Techniques: Expressing, In Vivo, Staining, Immunohistochemical staining, Control, Immunohistochemistry, Software, Immunofluorescence